Status:
COMPLETED
An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B
Lead Sponsor:
Novartis
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Hepatitis B
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is an extension study for patients who have previously completed Idenix Study NV-02B-003. This study is being conducted to compare the safety and effectiveness of treatment beyond 1 year of telbi...
Eligibility Criteria
Inclusion
- Patient has completed protocol NV-02B-003 without a serious adverse event attributed to study drug
- Patient remains seropositive for hepatitis B surface antigen (HBsAg)
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Patient is pregnant or breast-feeding
- Patient has signs of decompensated chronic hepatitis B
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00124241
End Date
November 1 2005
Last Update
May 12 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Los Angeles, California, United States
2
Toronto, Canada
3
Hong Kong, China
4
Paris, France